• Skip to main content
  • Skip to main content
Choose which site to search.
University of Arkansas for Medical Sciences Logo University of Arkansas for Medical Sciences
Psychiatric Research Institute
  • UAMS Health
  • Jobs
  • Giving
  • Clinical Care
    • Outpatient Care
      • AR ConnectNow
      • Center for Addiction Services and Treatment
        • Improving Access To Treatment For Opioid Use Disorder
        • MATRIARC
          • Project ECHO
        • Medication and Counseling Treatment
        • Medications To Treat Opioid Use Disorders
        • Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
        • Suboxone Treatment Program
        • Subutex Treatment Program
        • What is Buprenorphine?
        • What Is Methadone?
        • What Is Naltrexone?
        • What Is Vivitrol?
        • Drugs and Addiction
        • New Hybrid Care Program
        • Opioid Use Disorder
      • Child Study Center
        • Dialectical Behavior Therapy
        • Family Resources
          • Handouts for Parents
          • Books
          • Videos
        • Meet the Team – Child Study Center
        • Treatment and Services
      • Psychiatry Clinic in Fayetteville
        • Meet the Team
      • Six Bridges Clinic
      • STRIVE
      • Walker Family Clinic
        • Mental Health Resources
      • Women’s Mental Health Program
        • Peer Support Specialist Services
        • Reproductive Psychiatry Fellowship
        • Substance Use Treatment
        • WMHP Research
        • Women’s Inpatient Unit – 5 North
        • Women’s Mental Health Clinic
        • Women’s Mental Health Program – Fayetteville Branch
      • Odyssey Clinic
        • Northwest Arkansas Schizophrenia Conference 2025 Media
        • Schizophrenia Conference 2024 Media
      • Neuropsychology
    • Inpatient Units
      • Child Diagnostic Unit
        • Child Diagnostic Unit Videos
      • Women’s Inpatient Unit – 5 North
    • Interventional Psychiatry
      • Electroconvulsive Therapy
      • Esketamine
      • Ketamine Infusions
      • SAINT® Neuromodulation System
    • Crisis Stabilization Unit
      • Pulaski County Regional Crisis Stabilization Unit
        • Operation SAVE
  • News
  • PRI Journal
  • Education
  • Research
    • Center for Addiction Research
      • Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
      • What is Vivitrol?
      • Faculty
        • Alison Oliveto, Ph.D
        • Merideth Addicott, Ph.D.
        • Michael Mancino, M.D.
        • Nihit Kumar, M.D.
    • Center for Health Services Research
      • Behavioral Health QUERI
      • Health Services Research and Development Service
      • Rural Outreach Program
        • Rural Outreach Program Team
      • South Central (VISN 16) Mental Illness Research, Education and Clinical Center
      • Center for Health Services Research Faculty and Staff
        • Brandon J. Griffin, Ph.D.
        • Christopher Long, Ph.D.
        • Corey Hayes, Pharm.D., Ph.D., MPH
        • Eva Woodward, Ph.D.
        • Jacob Painter, Pharm.D, Ph.D.
        • Kent D. Hinkson, Ph.D.
        • Leah Tobey, PT, DPT, MBA
        • Marcela Weber, Ph.D.
        • Mary J. Bollinger, MPH, Ph.D.
        • Meghan Breckling, Pharm.D., BCACP
        • Melissa J. Zielinski, Ph.D.
        • Michael Cucciare, Ph.D.
        • Michael Wilson, M.D., Ph.D., FAAEM, FACEP
        • Prasad R. Padala, M.D., M.S., FACHE
        • Rajinder “Sonia” Singh, Ph.D.
        • Rebecca Raciborski, Ph.D.
        • Ronald G. Thompson, Jr., Ph.D., LCSW
        • Sara J. Landes, Ph.D.
        • Traci Abraham, Ph.D.
        • Angie Waliski, Ph.D.
        • Ellen P. Fischer, Ph.D.
        • Geoffrey M. Curran, Ph.D.
        • Greer Sullivan, M.D., M.S.P.H.
        • Jeffrey M. Pyne, M.D.
        • JoAnn Kirchner, M.D.
        • Joy Reeves Pemberton, Ph.D.
        • Karen Drummond, Ph.D.
        • Kristen M. Viverito, Psy.D.
        • Puru Thapa, M.D., M.P.H.
        • Richard R. Owen, M.D.
        • Teresa Hudson, Pharm.D., Ph.D.
        • Teresa L. Kramer, Ph.D.
      • Postdoctoral Fellowship
        • CeMHOR/HSR&D
        • MIRECC
    • Health and the Legal System (HEALS) Lab
      • Projects in the Health and the Legal System (HEALS) Lab
      • Publications and Media
      • About the HEALS Lab
    • Neurodevelopmental Risk and Resilience Program
    • Research Trials
    • Trauma REsilience & Community Collaboration (TRECC)
      • About TRECC
      • Get Involved
      • Research
        • Current Projects
        • Media
        • Selected Research Publications
      • Resources
        • Measures
        • Tools And Tool Kits
    • Helen L. Porter and James T. Dyke Brain Imaging Research Center
  • Patients and Visitors
    • Art of the Psychiatric Research Institute
    • Mental Health Resources
    • Mission And Vision Statements
    • Social Media
    • Women’s Mental Health Forum
    • Map and Directions
    • Job Openings
    • Faculty and Staff
    • Giving
  1. University of Arkansas for Medical Sciences
  2. Psychiatric Research Institute
  3. Clinical Care at the UAMS Psychiatric Research Institute
  4. Outpatient Care at the UAMS Psychiatric Research Institute
  5. Center for Addiction Services and Treatment
  6. Medication and Counseling Treatment

Medication and Counseling Treatment

Medication-assisted treatment (MAT) is the use of medications with counseling and behavioral therapies to treat substance use disorders and prevent opioid overdose. Research shows that a combination of medication and therapy can successfully treat these disorders and, for some people struggling with addiction, medication-assisted treatment can help sustain recovery.

Medication-assisted treatment is primarily used for the treatment of addiction to opioids such as heroin and prescription pain relievers that contain opiates. The prescribed medication operates to normalize brain chemistry, block the euphoric effects of alcohol and opioids, relieve physiological cravings, and normalize body functions without the negative effects of the abused drug.

Medications used in medication-assisted treatment are approved by the Food and Drug Administration (FDA), and medication-assisted treatment programs are clinically driven and tailored to meet each patient’s needs.

Combining medications used in medication-assisted treatment with anxiety treatment medications can be fatal. Types of anxiety treatment medications include derivatives of Benzodiazepine, such as Xanax or Valium.

Counseling and Behavioral Therapies

Under federal law, medication-assisted treatment patients must receive counseling, which could include different forms of behavioral therapy. These services are required along with medical, vocational, educational, and other assessment and treatment services.

Medication-assisted Treatment Effectiveness

The ultimate goal of medication-assisted treatment is full recovery, including the ability to live a self-directed life. This treatment approach has been shown to:

  • Improve patient survival
  • Increase retention in treatment
  • Decrease illicit opiate use and other criminal activity among people with substance use disorders
  • Increase patients’ ability to gain and maintain employment
  • Improve birth outcomes among women who have substance use disorders and are pregnant

Research also shows that these medications and therapies can contribute to lowering a person’s risk of contracting HIV or hepatitis C by reducing the potential for relapse.

Unfortunately, medication-assisted treatment is greatly underused. The slow adoption of these evidence-based treatment options for alcohol and opioid dependence is partly due to misconceptions about substituting one drug for another. Discrimination against medication-assisted treatment patients is also a factor, despite state and federal laws clearly prohibiting it. Other factors include lack of training for physicians and negative opinions toward medication-assisted treatment in communities and among health care professionals.

Medications Used in Medication-assisted Treatment

The Food and Drug Administration has approved several different medications to treat opioid addiction and alcohol dependence.

A common misconception associated with medication-assisted treatment is that it substitutes one drug for another. Instead, these medications relieve the withdrawal symptoms and psychological cravings that cause chemical imbalances in the body.

Medication-assisted treatment programs provide a safe and controlled level of medication to overcome the use of an abused opioid. When provided at the proper dose, medications used in medication-assisted treatment have no adverse effects on a person’s intelligence, mental capability, physical functioning, or employability.

Medications used in medication-assisted treatment for opioid treatment can only be dispensed through a SAMHSA-certified opioid treatment program. Some of the medications used in medication-assisted treatment are controlled substances due to their potential for misuse.

Opioid Treatment Programs

Opioid treatment programs (OTPs) provide medication-assisted treatment for individuals diagnosed with an opioid use disorder. Opioid treatment programs also provide a range of services to reduce, eliminate, or prevent the use of illicit drugs, potential criminal activity, and/or the spread of infectious disease. Opioid treatment programs focus on improving the quality of life of those receiving treatment.

Opioid treatment programs must be accredited by a SAMHSA-approved accrediting body and certified by SAMHSA. The Division of Pharmacologic Therapies (DPT), part of the SAMHSA Center for Substance Abuse Treatment (CSAT), oversees accreditation standards and certification processes for opioid treatment programs.

Federal law requires patients who receive treatment in an opioid treatment program to receive medical, counseling, vocational, educational, and other assessment and treatment services, in addition to prescribed medication.

Psychiatric Research Institute LogoPsychiatric Research InstitutePsychiatric Research Institute
Mailing Address: 4224 Shuffield Drive, Little Rock, AR 72205
Phone: (501) 526-8100
  • Facebook
  • X
  • Instagram
  • YouTube
  • LinkedIn
  • Pinterest
  • Disclaimer
  • Terms of Use
  • Privacy Statement

© 2025 University of Arkansas for Medical Sciences